Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways

IL-22 may play an accelerating role in the development of TNBC and may open a new therapeutic approach for TNBC.